Abstract:Nonsmall cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Herein, we develop a polypeptide-based block ionomer complex formed by anionic methoxy poly(ethylene glycol)-b-poly(L-glutamic acid) (mPEG-b-PLG) and cationic anticancer drug doxorubicin hydrochloride (DOX·HCl) for NSCLC treatment. This complex spontaneously self-assembled into spherical nanoparticles (NPs) in aqueous solutions via electrostatic interaction and hydrophobic stack, with a high loading efficiency (almost 100%) and negative surface charge. DOX·HCl release from the drug-loaded micellar nanoparticles (mPEG-b-PLG-DOX·HCl) was slow at physiological pH, but obviously increased at the acidic pH mimicking the endosomal/lysosomal environment. In vitro cytotoxicity and hemolysis assays demonstrated that the block copolypeptide was cytocompatible and hemocompatible, and the presence of copolypeptide carrier could reduce the hemolysis ratio of DOX·HCl significantly. Cellular uptake and cytotoxicity studies suggested that mPEG-b-PLG-DOX·HCl was taken up by A549 cells via endocytosis, with a slightly slower cellular internalization and lower cytotoxicity compared with free DOX·HCl. The pharmacokinetics study in rats showed that DOX·HCl-loaded micellar NPs significantly prolonged the blood circulation time. Moreover, mPEG-b-PLG-DOX·HCl exhibited enhanced therapeutic efficacy, increased apoptosis in tumor tissues, and reduced systemic toxicity in nude mice bearing A549 lung cancer xenograft compared with free DOX·HCl, which were further confirmed by histological and immunohistochemical analyses. The results demonstrated that mPEG-b-PLG was a promising vector to deliver DOX·HCl into tumors and achieve improved pharmacokinetics, biodistribution and efficacy of DOX·HCl with reduced toxicity. These features strongly supported the interest of developing mPEG-b-PLG-DOX·HCl as a valid therapeutic modality in the therapy of human NSCLC and other solid tumors.

Aminoglucose-functionalized, redox-responsive polymer nanomicelles for overcoming chemoresistance in lung cancer cells

Redox-Responsive Polyphosphoester-Based Micellar Nanomedicines for Overriding Chemoresistance in Breast Cancer Cells.

Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.

Effective treatment of drug-resistant lung cancer via a nanogel capable of reactivating cisplatin and enhancing early apoptosis

Enhanced Efficacy against Drug-Resistant Tumors Enabled by Redox-Responsive Mesoporous-Silica-Nanoparticle-Supported Lipid Bilayers as Targeted Delivery Vehicles

Tpgs-Functionalized Polydopamine-Modified Mesoporous Silica As Drug Nanocarriers for Enhanced Lung Cancer Chemotherapy Against Multidrug Resistance

Hybrid Micelles Based on Pt (IV) Polymeric Prodrug and TPGS for the Enhanced Cytotoxicity in Drug-Resistant Lung Cancer Cells

Overcoming Drug-Resistant Lung Cancer by Paclitaxel Loaded Dual-Functional Liposomes with Mitochondria Targeting and Ph-Response.

Paclitaxel-loaded and folic acid-modified PLGA nanomedicine with glutathione response for the treatment of lung cancer

Nanoscaled Poly(l-Glutamic Acid)/doxorubicin-Amphiphile Complex As Ph-Responsive Drug Delivery System for Effective Treatment of Nonsmall Cell Lung Cancer.

Biofunctionalized Polymer-Lipid Supported Mesoporous Silica Nanoparticles for Release of Chemotherapeutics in Multidrug Resistant Cancer Cells

Dual-responsive Mpeg-Plga-pglu Hybrid-Core Nanoparticles with a High Drug Loading to Reverse the Multidrug Resistance of Breast Cancer: an in Vitro and in Vivo Evaluation.

Ph-Triggered Surface Charge-Switchable Polymer Micelles for the Co-Delivery of Paclitaxel/disulfiram and Overcoming Multidrug Resistance in Cancer

Co-delivery of Doxorubicin and Afatinib with Ph-Responsive Polymeric Nanovesicle for Enhanced Lung Cancer Therapy

Mitochondrial Targeting and Ph-Responsive Nanogels for Co-Delivery of Lonidamine and Paclitaxel to Conquer Drug Resistance.

Paclitaxel and Quercetin Co-Loaded Functional Mesoporous Silica Nanoparticles Overcoming Multidrug Resistance in Breast Cancer

Overcoming Tumor Resistance to Cisplatin by Cationic Lipid-Assisted Prodrug Nanoparticles.

Low-molecular-weight Protamine-Modified PLGA Nanoparticles for Overcoming Drug-Resistant Breast Cancer.

Glutathione-Responsive Plga Nanocomplex For Dual Delivery Of Doxorubicin And Curcumin To Overcome Tumor Multidrug Resistance

pH- and photothermal-driven multistage delivery nanoplatform for overcoming cancer drug resistance.

Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance